Cerus Endovascular manufactures devices for the treatment for intracranial aneurysms. Credit: Romanova Natali via Shutterstock.com.

Medical technology company Stryker has closed the acquisition of US-based commercial-stage, medical device company Cerus Endovascular.

Cerus Endovascular is involved in the design, development, manufacture and supply of interventional neurovascular devices and delivery systems used by neuroradiologists for the treatment of intracranial aneurysms.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The devices are used in the treatment of acute, life-threatening neurological conditions.

The company’s offerings include the Contour Neurovascular System and the Neqstent Coil Assisted Flow Diverter. These products are CE-marked and are expected to expand Stryker’s existing portfolio of aneurysm treatment solutions.

Stryker’s neurovascular division president Jim Marucci said: “The acquisition of Cerus Endovascular is highly complementary to Stryker’s Neurovascular business, and strengthens our haemorrhagic portfolio globally.

“We look forward to working with the Cerus team to deliver on our mission of making healthcare better. Together, we will enable physicians to treat a broader range of aneurysms.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Stryker’s Neurovascular division is focused on technology for the endovascular treatment of aneurysms. The addition of Cerus Endovascular’s portfolio is expected to accommodate the increasing demand for one-and-done intrasaccular aneurysm therapy.

The transaction came after a competitive auction process initiated by Cerus. Stryker and Cerus signed a definitive agreement for the deal in September 2022. 

Global law firm Dechert was appointed by Cerus Endovascular to advise on the deal with Stryker.

UK regulatory body Competition and Markets Authority (CMA) reviewed the impact of the acquisition on competition in the UK market in February this year.

Last month, the CMA approved the acquisition, paving the way for the completion of the deal.

Stryker provides products and services in the areas of medical and surgical, neurotechnology, orthopaedics and spine.

In February this year, the company received 510(k) clearance from the US Food and Drug Administration for its Q Guidance System with Cranial Guidance Software for cranial applications.